source
- STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededEli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
- Eli Lilly announces second partnership this year to advance recombinase-based gene editingEli Lilly has entered a second partnership this year aimed at developing recombinase-based gene‑editing technologies. The collaboration follows earlier efforts to explore enzymes that can precisely…